The global Heparin market is anticipated to grow at a CAGR of 6.5% during the forecast period. Heparin is a blood thinner or disaccharide anticoagulant that prevents the formation of blood clots. They are produced in the body by mast cells and basophils. It is a naturally occurring anticoagulant that is released from mast cells. Heparin is also called as Unfractionated heparin (UH). It is a heterogeneous preparation of anionic, sulfated glycosaminoglycan polymer. Its mechanism of action includes binding reversibly to antithrombin III (ATIII) and significantly escalates the rate at which ATIII inactivates coagulation enzymes factor Xa and thrombin (factor IIa).

Top Driver: Rise in the Prevalence of Venous Thrombosis and Extended Application of Heparin

The rise in the prevalence of venous thrombosis owing to various factors such as cardiovascular diseases stimulates the growth of the global heparin market. In addition to this, the application of heparin in various surgeries such as heart surgeries and orthopedic and growth in the number of patients undergoing such surgeries further propelled the growth of the market. On the other hand, several adverse side-effects associated with heparin, such as heparin-induced thrombocytopenia, hamper the growth of the market. Moreover, as heparin is derived from animal sources, there are significant safety and supply issues, which further hampers the growth of the market. On the contrary, the availability of synthetic and semi-synthetic heparin mimetics that aids in treating various cancers, coagulation, and inflammatory diseases is anticipated to create lucrative opportunities for adopting heparin products. Moreover, the rise in government funding toward improving healthcare infrastructure and extensive research and development (R&D) activities to develop heparin with enhanced therapeutic potential is expected to fuel the market.

Low Molecular Weight Segment is Anticipated to Witness the Significant Growth

The global heparin market is segmented into low molecular weight, ultra-low molecular weight, and unfractionated heparin based on type. The low molecular weight segment holds the largest heparin market share owing to the promising anticoagulant effect. In addition to this, as per a study published in NEJM Journal Watch, a low incidence of heparin-induced thrombocytopenia contributes towards the segment growth. Ultra-low molecular weight heparin is expected to be the fastest-growing segment over the forecast period owing to the commercialization of products with improved pharmacological effects. Based on the source, the market is segmented into bovine and porcine. Based on the application, the market is segmented into venous thromboembolism, atrial fibrillation, renal impairment, and others.

The Increasing Prevalence of Long-term Survivors of Acute Myocardial Infarction (AMI) to Benefit Europe Market 

On the basis of region, the global heparin market is segmented into North America, Europe, Asia Pacific, and SAMEA. Europe’s heparin market is expected to grow at a significant pace during the forecast period due to the rising geriatric population and the increasing prevalence of long-term survivors of acute myocardial infarction (AMI). Following Europe, the Asia Pacific heparin market is estimated to grow at a considerable rate during the forecast period due to the increasing prevalence of myocardial infarction among the regional population.

Players to Focus on Product Innovation 

The global heparin market is estimated to stay fragmented during the forecast period owing to the new entrants. Major players operating in market are Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.

1. Braun Medical Inc.: In April 2019, B. Braun Medical Inc. introduced Heparin Sodium Injection, USP – the first Heparin 5,000 USP Unit / 0.5 mL prefilled syringe with attached safety needle for intravenous and subcutaneous use in the United States.

Scope of the Report

By Type

• Low molecular weight
• Ultra-low molecular weight
• U1nfractionated heparin

By Source  

• Bovine
• Porcine

By Application  

• Atrial fibrillation
• Venous thromboembolism
• Renal impairment
• Others

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.